GHK-Cu Excess Exposure: Separate Product Error From Copper Toxicology

Start With the Person and Product, Not a Copper Calculator

The legacy page supplied elemental-copper conversions, laboratory cutoffs, chelator doses, home monitoring, and a table labeling particular injected amounts “low,” “moderate,” or “high” risk. Those thresholds came from oral nutrient or copper-poisoning literature, not a human GHK-Cu overdose study.

General copper toxicology still matters, but its boundary must remain visible. The NIH Office of Dietary Supplements states:

“Chronic exposure to high levels of copper can result in liver damage and gastrointestinal symptoms (e.g., abdominal pain, cramps, nausea, diarrhea, and vomiting).”

The issuer is the NIH Office of Dietary Supplements in Copper: Fact Sheet for Health Professionals, under “Health Risks from Excessive Copper.” The excerpt concerns chronic high copper exposure generally. It does not define a GHK-Cu syndrome, injected dose threshold, observation period, or treatment plan, and it does not endorse GHK-Cu or HealthRX.com.

Call emergency services immediately if the person collapses, has a seizure, has trouble breathing, or cannot be awakened. In the United States, Poison Control provides case-specific guidance at 1-800-222-1222 or poison.org.

Why Dietary Limits Cannot Grade an Injection Error

The adult tolerable upper intake level for copper is 10,000 micrograms per day. NIH explicitly defines that limit for copper from food and supplements in generally healthy people. It is not:

• an injected GHK-Cu dose;
• a maximum tolerated peptide dose;
• a one-time poison threshold;
• a blood-copper treatment trigger; or
• a safe conversion factor for an uncertain vial.

An elemental-copper calculation may describe part of a labeled molecule. It cannot resolve whether the vial contains the stated material, whether the concentration is correct, how route changes exposure, or whether peptide-related impurities and aggregation are present.

FDA's current GHK-Cu entry is route-specific: compounded injectable products may pose immunogenicity risk because of aggregation and peptide-related impurities, and human data are limited. Those product risks are not captured by a copper milligram total.

The Two-Track Exposure Record

An excess exposure has at least two simultaneous tracks. Gather what is available without delaying urgent care.

The distinction matters. An extra amount of correctly identified material is one question. A mislabeled, over-concentrated, contaminated, degraded, or aggregated product is another.

What Not to Do

• Do not induce vomiting.
• Do not inject another substance to “balance” the exposure.
• Do not start zinc, penicillamine, trientine, EDTA, or another chelator without case-specific medical direction.
• Do not use a dietary upper limit to decide that an injection is safe.
• Do not request or interpret a single serum copper result as a do-it-yourself diagnosis.
• Do not discard the vial, packaging, or preparation instructions.
• Do not wait for a fixed online observation window when Poison Control or emergency assessment is indicated.

The food-and-supplement interaction audit explains why copper and zinc nutrient facts do not become peptide timing rules. The special-populations evidence map covers Wilson disease and organ-disease uncertainty, while the cancer-risk review keeps repair biology separate from toxicology.

Symptoms Do Not Identify the Molecule

Nausea, vomiting, abdominal pain, neurologic symptoms, or liver injury can occur for many reasons. General copper toxicity literature can inform a poison specialist, but symptoms alone cannot prove:

• the vial contained GHK-Cu;
• copper caused the event;
• an impurity or contaminant was absent;
• a particular concentration was used; or
• a home antidote is appropriate.

This is why product traceability and co-exposure history belong beside symptoms.

Why the Current Trial Does Not Supply an Overdose Protocol

NCT07437586 is a recruiting study of topical 0.1% GHK-Cu gel on controlled skin wounds in healthy adults. No results are posted. A planned topical regimen cannot define:

• an injected overdose threshold;
• the safety of a compounded vial;
• a treatment algorithm;
• a chelation trigger; or
• an observation duration after an error.

Those require administered-human toxicology, pharmacokinetics, product characterization, and case evidence that are not currently available.

Reporting a Product Problem

If a clinician suspects an adverse event or product-quality problem, FDA's MedWatch program accepts reports involving unapproved and compounded products. A report does not prove causation. It preserves the lot, product, route, symptoms, and timing needed to evaluate a signal.

Keep photographs and packaging until Poison Control, the treating team, pharmacy, or regulator says they are no longer needed.

The Responsible Bottom Line

This page can provide emergency triage and a two-track exposure record. It cannot responsibly provide a lethal dose, “safe extra dose,” home chelation plan, laboratory threshold, or fixed monitoring window.

Medical review of this revision is pending. NIH, FDA, Poison Control, trial sponsors, and study authors do not endorse GHK-Cu, HealthRX.com, or this page.